A Phase 3, randomized, double-blind study with Tivantini

Project: Research project

Project Details

Description

A Phase 3, randomized, double-blind study with Tivantinib (ARQ 197) in subjects with met diagnostic-high inoperable hepatocellular carcinoma (HCC) treated with one prior systemic therapy
StatusFinished
Effective start/end date5/1/138/30/18

Funding

  • DAIICHI SANKYO PHARM DEV

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.